Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by itntdfon Dec 27, 2022 5:22pm
181 Views
Post# 35192838

RE:RE:RE:Where we are now as ONCY shareholders

RE:RE:RE:Where we are now as ONCY shareholderssince reo/pela has typically been used as a salvage treatment, it has never been able to show its true benefit.

administering as a "last resort" is one of the main reasons for viewing oncy as a lost cause.

recent results indicate that administering pela sooner rather than later produces real results.

if administration of pela is done before the body's immune system is pretty well shot from chemo/radiation it will be given the time it needs to do what it does.

it's been within the last year that corporate presentation material definitively proved that pela takes many weeks/months to get the immune system to kick in.  therefore, administering pela as part of a first line regimen should produce the convincing results oncy needs to get things moving.

this is why we are waiting a few more months to let data mature and why, among other reasons like inability to fill slots in the trials because of covid issues or supply chain issues dealing with our pela production, that we are being told "next year".  

something cubs fans have been told many times over and why for those of us who have been around for a long time (not measured by how many posts have been made on one board or another or when an alias was created) remember oncy's old saw "in the not too distant future".

maybe that's in the forseeable future now.
<< Previous
Bullboard Posts
Next >>